Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stivarga and Pembrolizumab in Advanced Hepatocellular Carcinoma
NCT03347292Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of regorafenib in hepatocellular carcinoma (HCC), sponsored by Bayer. Primary endpoint: Treatment-Emergent Adverse Events. Started Jun 2018; status: completed.
02
Drugs
regorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03347292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03347292.